{"created":"2023-05-15T16:13:13.148803+00:00","id":43750,"links":{},"metadata":{"_buckets":{"deposit":"b1f423ab-4d96-453f-9265-0295fb351321"},"_deposit":{"created_by":25,"id":"43750","owners":[25],"pid":{"revision_id":0,"type":"depid","value":"43750"},"status":"published"},"_oai":{"id":"oai:shinshu.repo.nii.ac.jp:00043750","sets":["2668"]},"author_link":["169909","169916","169907","169913","169908","169906","169910","169915","169917","169914","169911","169912"],"item_20002_biblio_info_27":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-09-26","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"1004","bibliographicPageStart":"997","bibliographicVolumeNumber":"76","bibliographic_titles":[{"bibliographic_title":"CANCER CHEMOTHERAPY AND PHARMACOLOGY"}]}]},"item_20002_creator_3":{"attribute_name":"作成者(その他言語)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yamazaki, N."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kiyohara, Y."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uhara, H."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukushima, S."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uchi, H."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shibagaki, N."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsutsumida, A."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yoshikawa, S."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okuyama, R."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ito, Y."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tokudome, T."}],"nameIdentifiers":[{}]}]},"item_20002_date_19":{"attribute_name":"日付","attribute_value_mlt":[{"subitem_date_issued_datetime":"2018-10-31","subitem_date_issued_type":"Created"}]},"item_20002_description_14":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"PurposeIpilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma.MethodsPatients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015).ResultsData are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively.ConclusionIpilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients.","subitem_description_type":"Other"}]},"item_20002_description_20":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_20002_description_22":{"attribute_name":"その他の資源識別子","attribute_value_mlt":[{"subitem_description":"CANCER CHEMOTHERAPY AND PHARMACOLOGY.76(5):997-1004(2015)","subitem_description_type":"Other"}]},"item_20002_full_name_16":{"attribute_name":"公開者(その他言語)","attribute_value_mlt":[{"nameIdentifiers":[{}],"names":[{"name":"SPRINGER"}]}]},"item_20002_identifier_23":{"attribute_name":"資源識別子URI","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/10091/00020987"}]},"item_20002_relation_31":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.ncbi.nlm.nih.gov/pubmed/26410424","subitem_relation_type_select":"PMID"}}]},"item_20002_relation_32":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s00280-015-2873-x","subitem_relation_type_select":"DOI"}}]},"item_20002_rights_50":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made."},{"subitem_rights":"© The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made."}]},"item_20002_source_id_25":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0344-5704","subitem_source_identifier_type":"ISSN"}]},"item_20002_source_id_26":{"attribute_name":"処理レコードID(総合目録DB)","attribute_value_mlt":[{"subitem_source_identifier":"AA00598397","subitem_source_identifier_type":"NCID"}]},"item_20002_version_type_51":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"url":{"url":"https://soar-ir.repo.nii.ac.jp/?action=repository_action_common_download&item_id=20229&item_no=1&attribute_id=65&file_no=1"}}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Ipilimumab","subitem_subject_scheme":"Other"},{"subitem_subject":"Immune-checkpoint inhibitor","subitem_subject_scheme":"Other"},{"subitem_subject":"Melanoma Phase II study","subitem_subject_scheme":"Other"},{"subitem_subject":"Japanese patients","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma"}]},"item_type_id":"20002","owner":"25","path":["2668"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-09-04"},"publish_date":"2020-09-04","publish_status":"0","recid":"43750","relation_version_is_last":true,"title":["Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma"],"weko_creator_id":"25","weko_shared_id":-1},"updated":"2023-05-15T18:21:01.024957+00:00"}